Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BAFNA PHARMA vs MERCURY LAB. - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BAFNA PHARMA MERCURY LAB. BAFNA PHARMA/
MERCURY LAB.
 
P/E (TTM) x 16.1 24.3 66.3% View Chart
P/BV x 2.5 2.2 112.8% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 BAFNA PHARMA   MERCURY LAB.
EQUITY SHARE DATA
    BAFNA PHARMA
Mar-23
MERCURY LAB.
Mar-23
BAFNA PHARMA/
MERCURY LAB.
5-Yr Chart
Click to enlarge
High Rs1411,000 14.1%   
Low Rs79390 20.1%   
Sales per share (Unadj.) Rs48.8627.8 7.8%  
Earnings per share (Unadj.) Rs4.846.5 10.3%  
Cash flow per share (Unadj.) Rs7.067.2 10.5%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Avg Dividend yield %00.5 0.0%  
Book value per share (Unadj.) Rs31.0380.2 8.2%  
Shares outstanding (eoy) m23.661.20 1,971.7%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.31.1 203.3%   
Avg P/E ratio x22.914.9 153.2%  
P/CF ratio (eoy) x15.610.3 150.5%  
Price / Book Value ratio x3.51.8 193.4%  
Dividend payout %07.5 0.0%   
Avg Mkt Cap Rs m2,596834 311.3%   
No. of employees `000NANA-   
Total wages/salary Rs m159139 114.1%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m1,154753 153.1%  
Other income Rs m3317 190.4%   
Total revenues Rs m1,186771 153.9%   
Gross profit Rs m15786 182.3%  
Depreciation Rs m5325 214.8%   
Interest Rs m204 563.0%   
Profit before tax Rs m11675 155.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m319 14.5%   
Profit after tax Rs m11356 203.2%  
Gross profit margin %13.611.4 119.1%  
Effective tax rate %2.425.5 9.4%   
Net profit margin %9.87.4 132.7%  
BALANCE SHEET DATA
Current assets Rs m873417 209.3%   
Current liabilities Rs m465164 282.9%   
Net working cap to sales %35.433.6 105.5%  
Current ratio x1.92.5 74.0%  
Inventory Days Days27 24.0%  
Debtors Days Days1,3021,035 125.8%  
Net fixed assets Rs m423259 163.4%   
Share capital Rs m23712 1,971.3%   
"Free" reserves Rs m498444 112.1%   
Net worth Rs m735456 161.0%   
Long term debt Rs m8424 348.3%   
Total assets Rs m1,296676 191.8%  
Interest coverage x6.721.7 30.9%   
Debt to equity ratio x0.10.1 216.4%  
Sales to assets ratio x0.91.1 79.8%   
Return on assets %10.38.8 117.4%  
Return on equity %15.412.2 126.2%  
Return on capital %16.716.3 102.0%  
Exports to sales %025.3 0.0%   
Imports to sales %7.90.4 2,233.1%   
Exports (fob) Rs mNA191 0.0%   
Imports (cif) Rs m913 3,419.2%   
Fx inflow Rs m885191 464.0%   
Fx outflow Rs m918 1,147.0%   
Net fx Rs m794183 434.5%   
CASH FLOW
From Operations Rs m5025 202.0%  
From Investments Rs m-75-11 708.9%  
From Financial Activity Rs m102-10 -1,004.6%  
Net Cashflow Rs m764 1,994.0%  

Share Holding

Indian Promoters % 88.4 73.7 120.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 11.6 26.3 43.9%  
Shareholders   7,367 1,161 634.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BAFNA PHARMA With:   DIVIS LABORATORIES    CIPLA    SUN PHARMA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    


More on BAFNA PHARM. vs MERCURY LAB.

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

BAFNA PHARM. vs MERCURY LAB. Share Price Performance

Period BAFNA PHARM. MERCURY LAB. S&P BSE HEALTHCARE
1-Day -1.07% -4.12% 1.18%
1-Month -11.71% -3.92% -0.75%
1-Year -4.18% 56.06% 61.82%
3-Year CAGR -19.05% 9.86% 18.16%
5-Year CAGR 47.58% 20.84% 19.79%

* Compound Annual Growth Rate

Here are more details on the BAFNA PHARM. share price and the MERCURY LAB. share price.

Moving on to shareholding structures...

The promoters of BAFNA PHARM. hold a 88.4% stake in the company. In case of MERCURY LAB. the stake stands at 73.7%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BAFNA PHARM. and the shareholding pattern of MERCURY LAB..

Finally, a word on dividends...

In the most recent financial year, BAFNA PHARM. paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of 0.0%.

MERCURY LAB. paid Rs 3.5, and its dividend payout ratio stood at 7.5%.

You may visit here to review the dividend history of BAFNA PHARM., and the dividend history of MERCURY LAB..

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.